Podcasts/Dr. Neil Love/Breast Cancer Update
Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Breast Cancer Update•byDr. Neil Love

Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases

0:000:00
Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer. CME information and select publications here .
🏢 Dr. Neil Love•87 Episodes•0 Subscribers•0 Total Listens

Episode Playlist

25 Episodes
Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Dec 23, 2025•—

Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting
Dec 8, 2025•—

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting

Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dec 5, 2025•—

Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Dec 2, 2025•—

Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2
Nov 29, 2025•—

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates
Nov 26, 2025•—

Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders
Nov 20, 2025•—

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs
Nov 14, 2025•—

ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs

Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 10, 2025•—

Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders
Nov 5, 2025•—

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Oct 27, 2025•—

Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
Oct 21, 2025•—

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Oct 14, 2025•—

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

Breast Cancer — An ASCO 2025 Review
Oct 7, 2025•—

Breast Cancer — An ASCO 2025 Review

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Sep 29, 2025•—

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
Sep 23, 2025•—

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy
Sep 18, 2025•—

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management
Sep 16, 2025•—

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management
Sep 15, 2025•—

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1
Sep 9, 2025•—

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Sep 1, 2025•—

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches
Aug 26, 2025•—

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Aug 4, 2025•—

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management
Jul 29, 2025•—

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting
Jul 4, 2025•—

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

おすすめ